JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$3.21B |
| 2 |
Arthur J. Gallagher & Co
AJG
|
+$2.24B |
| 3 |
Walt Disney
DIS
|
+$2.18B |
| 4 |
Walmart Inc
WMT
|
+$1.96B |
| 5 |
McDonald's
MCD
|
+$1.91B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$2.77B |
| 2 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$2.64B |
| 3 |
Vanguard Long-Term Treasury ETF
VGLT
|
+$2.5B |
| 4 |
iShares Broad USD High Yield Corporate Bond ETF
USHY
|
+$2.23B |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.17% |
| 2 | Financials | 10.12% |
| 3 | Consumer Discretionary | 9.84% |
| 4 | Healthcare | 7.97% |
| 5 | Communication Services | 6.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2926
Cellebrite
CLBT
$2.78B
| $7.31M | ﹤0.01% |
331,665
-95,990
| -22% | -$1.85M |
|
2927
CALL
Phillips 66
PSX
$93.2B
| $7.28M | ﹤0.01% |
63,900
+20,000
| +46% | +$2.54M |
|
2928
CALL
British American Tobacco
BTI
$123B
| $7.26M | ﹤0.01% |
200,000
| – | – |
|
2929
CALL
Nu Holdings
NU
$73.6B
| $7.25M | ﹤0.01% |
700,000
-313,000
| -31% | -$4.16M |
|
2930
Dimensional Emerging Core Equity Market ETF
DFAE
$9.83B
| $7.24M | ﹤0.01% |
285,207
+62,916
| +28% | +$1.66M |
|
2931
Teekay
TK
$1.09B
| $7.23M | ﹤0.01% |
1,043,479
+338,105
| +48% | +$2.61M |
|
2932
Ezcorp Inc
EZPW
$1.81B
| $7.21M | ﹤0.01% |
590,016
+164,260
| +39% | +$1.95M |
|
2933
CALL
Stryker
SYK
$130B
| $7.2M | ﹤0.01% |
20,000
| – | – |
|
2934
1st Source
SRCE
$2.13B
| $7.2M | ﹤0.01% |
123,276
+32,257
| +35% | +$2M |
|
2935
Adtran
ADTN
$684M
| $7.2M | ﹤0.01% |
863,807
+738,893
| +592% | +$5.45M |
|
2936
ODDITY Tech
ODD
$605M
| $7.18M | ﹤0.01% |
170,878
+46,776
| +38% | +$2.01M |
|
2937
CTS Corp
CTS
$1.81B
| $7.17M | ﹤0.01% |
135,969
+57,135
| +72% | +$2.99M |
|
2938
PIMCO Short Term Municipal Bond Active Exchange-Traded Fund
SMMU
$1.17B
| $7.16M | ﹤0.01% |
143,596
+90,640
| +171% | +$4.54M |
|
2939
Tarsus Pharmaceuticals
TARS
$3.04B
| $7.15M | ﹤0.01% |
129,184
-310,983
| -71% | -$14.1M |
|
2940
Recursion Pharmaceuticals
RXRX
$1.69B
| $7.15M | ﹤0.01% |
1,057,167
-119,024
| -10% | -$800K |
|
2941
PRA Group
PRAA
$776M
| $7.14M | ﹤0.01% |
341,952
+267,015
| +356% | +$5.7M |
|
2942
Star Group
SGU
$415M
| $7.13M | ﹤0.01% |
618,189
-4,384
| -0.7% | -$51.6K |
|
2943
Avantis Emerging Markets Equity ETF
AVEM
$26.9B
| $7.1M | ﹤0.01% |
120,771
-8,974
| -7% | -$559K |
|
2944
Perrigo
PRGO
$1.81B
| $7.07M | ﹤0.01% |
275,151
-265,849
| -49% | -$6.98M |
|
2945
Sprout Social
SPT
$599M
| $7.07M | ﹤0.01% |
230,248
-172,699
| -43% | -$5.19M |
|
2946
IDEAYA Biosciences
IDYA
$3.49B
| $7.06M | ﹤0.01% |
274,693
+194,913
| +244% | +$5.52M |
|
2947
HCI Group
HCI
$2.29B
| $7.06M | ﹤0.01% |
60,557
-10,348
| -15% | -$1.18M |
|
2948
SolarEdge
SEDG
$1.99B
| $7.05M | ﹤0.01% |
518,550
+92,720
| +22% | +$1.43M |
|
|
MPT
2949
Medical Properties Trust
MPT
$2.5B
| $7.04M | ﹤0.01% |
1,782,664
+77,879
| +5% | +$349K |
|
2950
PUT
Synopsys
SNPS
$80.7B
| $7.04M | ﹤0.01% |
14,500
-25,500
| -64% | -$13.3M |
|
Similar funds
JP Morgan Chase's Q4 2024 Portfolio in Review
As of Q4 2024, JP Morgan Chase held 7,917 positions worth $1.34T, up 2.1% from $1.32T the previous quarter. Its ten largest holdings account for 24% of the portfolio.
JP Morgan Chase's Q4 2024 filing shows 510 new, 3,353 increased, 2,466 reduced and 523 closed positions. Its largest new stake was Primo Brands: 3,989,501 shares worth $123M. The largest sale was Eli Lilly, an estimated $2.77B.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 23% a quarter earlier, followed by Financials and Consumer Discretionary.
- JP Morgan Chase's largest Q4 2024 buy was Primo Brands: 3,989,501 shares worth $123M.
- JP Morgan Chase added most to Broadcom in Q4 2024, an estimated $3.21B increase.
- JP Morgan Chase's biggest Q4 2024 reduction was Eli Lilly, cutting an estimated $2.77B.
- JP Morgan Chase fully exited Stericycle Inc in Q4 2024, selling an estimated $183M.
- JP Morgan Chase's ten largest holdings make up 24% of its $1.34T portfolio in Q4 2024.
- JP Morgan Chase opened 510 new positions and closed 523 in Q4 2024.
- JP Morgan Chase's portfolio value rose 2.1% quarter-over-quarter to $1.34T.
Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.